These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 27037842)

  • 21. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer.
    Saha A; Chatterjee SK
    Scand J Immunol; 2010 Feb; 71(2):70-82. PubMed ID: 20384858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.
    Fotin-Mleczek M; Duchardt KM; Lorenz C; Pfeiffer R; Ojkić-Zrna S; Probst J; Kallen KJ
    J Immunother; 2011 Jan; 34(1):1-15. PubMed ID: 21150709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogene therapy.
    Lichtor T; Glick RP
    Adv Exp Med Biol; 2012; 746():151-65. PubMed ID: 22639166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.
    Moeini S; Saeidi M; Fotouhi F; Mondanizadeh M; Shirian S; Mohebi A; Gorji A; Ghaemi A
    Arch Virol; 2017 Feb; 162(2):333-346. PubMed ID: 27699512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus.
    Kass E; Schlom J; Thompson J; Guadagni F; Graziano P; Greiner JW
    Cancer Res; 1999 Feb; 59(3):676-83. PubMed ID: 9973217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
    Aravindaram K; Wang PH; Yin SY; Yang NS
    Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
    Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
    Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.
    Gabitzsch ES; Tsang KY; Palena C; David JM; Fantini M; Kwilas A; Rice AE; Latchman Y; Hodge JW; Gulley JL; Madan RA; Heery CR; Balint JP; Jones FR; Schlom J
    Oncotarget; 2015 Oct; 6(31):31344-59. PubMed ID: 26374823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment and Prevention of Lung Cancer Using a Virus-Infected Reprogrammed Somatic Cell-Derived Tumor Cell Vaccination (VIReST) Regime.
    Zhang Z; Lu S; Dunmall LSC; Wang Z; Cheng Z; Zhang Z; Yan W; Chu Y; Gao D; Wang N; Li Y; Wang J; Li Y; Ji Y; Shan D; Li K; Wang P; Dong Y; Dong J; Lemoine NR; Pei D; Zhang L; Wang Y
    Front Immunol; 2020; 11():1996. PubMed ID: 32903551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice.
    Snyder LA; Goletz TJ; Gunn GR; Shi FF; Harris MC; Cochlin K; McCauley C; McCarthy SG; Branigan PJ; Knight DM
    Vaccine; 2006 Apr; 24(16):3340-52. PubMed ID: 16472547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A focused immune response targeting the homotypic binding domain of the carcinoembryonic antigen blocks the establishment of tumor foci in vivo.
    Abdul-Wahid A; Huang EH; Lu H; Flanagan J; Mallick AI; Gariépy J
    Int J Cancer; 2012 Dec; 131(12):2839-51. PubMed ID: 22495743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
    Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
    Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PolyI:C-Induced, TLR3/RIP3-Dependent Necroptosis Backs Up Immune Effector-Mediated Tumor Elimination In Vivo.
    Takemura R; Takaki H; Okada S; Shime H; Akazawa T; Oshiumi H; Matsumoto M; Teshima T; Seya T
    Cancer Immunol Res; 2015 Aug; 3(8):902-14. PubMed ID: 25898986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficient induction of anti-tumor immunity by a TAT-CEA fusion protein vaccine with poly(I:C) in a murine colorectal tumor model.
    Park JS; Kim HS; Park HM; Kim CH; Kim TG
    Vaccine; 2011 Nov; 29(47):8642-8. PubMed ID: 21945963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mast cell: insight into remodeling a tumor microenvironment.
    Liu J; Zhang Y; Zhao J; Yang Z; Li D; Katirai F; Huang B
    Cancer Metastasis Rev; 2011 Jun; 30(2):177-84. PubMed ID: 21267769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antigen-specific vaccines for cancer treatment.
    Tagliamonte M; Petrizzo A; Tornesello ML; Buonaguro FM; Buonaguro L
    Hum Vaccin Immunother; 2014; 10(11):3332-46. PubMed ID: 25483639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection.
    Schreurs MW; de Boer AJ; Figdor CG; Adema GJ
    Cancer Res; 1998 Jun; 58(12):2509-14. PubMed ID: 9635569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetically modified pancreatic carcinoma PANC-1 cells can act as cancer vaccine to enhance antitumor immune response in mice.
    Tao Y; Lin F; Li T; Xie J; Shen C; Zhu Z
    Oncol Res; 2013; 21(6):307-16. PubMed ID: 25198660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.